- Home
- MSSA vs CMRX Comparison
MSSA vs CMRX Comparison
Compare MSSA & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSSA
- CMRX
- Stock Information
- Founded
- MSSA 2021
- CMRX 2000
- Country
- MSSA United States
- CMRX United States
- Employees
- MSSA N/A
- CMRX N/A
- Industry
- MSSA
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- MSSA
- CMRX Health Care
- Exchange
- MSSA NYSE
- CMRX Nasdaq
- Market Cap
- MSSA 74.6M
- CMRX 77.1M
- IPO Year
- MSSA 2022
- CMRX 2013
- Fundamental
- Price
- MSSA $12.00
- CMRX $0.86
- Analyst Decision
- MSSA
- CMRX Strong Buy
- Analyst Count
- MSSA 0
- CMRX 1
- Target Price
- MSSA N/A
- CMRX $11.00
- AVG Volume (30 Days)
- MSSA 1.8K
- CMRX 282.9K
- Earning Date
- MSSA 01-01-0001
- CMRX 11-07-2024
- Dividend Yield
- MSSA N/A
- CMRX N/A
- EPS Growth
- MSSA N/A
- CMRX N/A
- EPS
- MSSA 0.20
- CMRX N/A
- Revenue
- MSSA N/A
- CMRX $159,000.00
- Revenue This Year
- MSSA N/A
- CMRX $1,772.84
- Revenue Next Year
- MSSA N/A
- CMRX N/A
- P/E Ratio
- MSSA $60.97
- CMRX N/A
- Revenue Growth
- MSSA N/A
- CMRX N/A
- 52 Week Low
- MSSA $10.89
- CMRX $0.75
- 52 Week High
- MSSA $12.00
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- MSSA 82.76
- CMRX 41.07
- Support Level
- MSSA $11.60
- CMRX $0.91
- Resistance Level
- MSSA $11.68
- CMRX $1.12
- Average True Range (ATR)
- MSSA 0.02
- CMRX 0.09
- MACD
- MSSA 0.01
- CMRX -0.01
- Stochastic Oscillator
- MSSA 100.00
- CMRX 10.31
About MSSA METAL SKY STAR ACQUISITION CORP
Metal Sky Star Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.